权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of necrosis in the evolution of highly metastatic and chemo-resistant breast cancers

坏死在高度转移性和化疗耐药性乳腺癌演变中的作用

基本信息

批准号：
10736486
负责人：
Kevin Jon Cheung
金额：
$ 64.2万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-23 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10736486
关键词：
Adjuvant Adjuvant Therapy Aftercare Aggressive behavior Aneuploidy Angiopoietins Animal Model Antineoplastic Agents Benefits and Risks Biological Availability Biological Models Blood Blood Vessels Blood flow Blood specimen Breast Cancer Cell Breast Cancer Detection Breast Cancer Patient Breast Cancer therapy Breast cancer metastasis Cell Death Cells Cessation of life Chemoresistance Clinical Complex DNA analysis Data Development Diagnosis Disease Dissection Distant Drug Delivery Systems Drug resistance Ecosystem Epidemiologist Evolution Family Generations Genes Genome Genomics Hand Heterogeneity Histologic Human Hypoxia Impairment Individual Malignant Neoplasms Mammary Neoplasms Metastatic Neoplasm to the Lung Metastatic breast cancer Modeling Molecular Mus Mutate Mutation Necrosis Necrosis Induction Neoadjuvant Therapy Neoplasm Metastasis Nutrient Organ Outcome Oxygen Patients Penetration Perfusion Pharmaceutical Preparations Phenotype Population Study Prevention Primary Neoplasm Prognostic Marker Protein Secretion Rattus Recurrence Recurrent Malignant Neoplasm Residual Cancers Resistance Risk Risk Factors Risk Reduction Role Sampling Source Testing Therapeutic Tissue Sample Tissues Toxic effect Tumor-Derived Woman Work aggressive therapy barrier to testing cancer recurrence cancer subtypes cancer therapy chemotherapy clinical prognostic cohort driving force drug development genomic signature improved innovation knock-down liquid biopsy malignant breast neoplasm member molecular marker mouse model neoplastic cell patient derived xenograft model population based prevent prognostic prognostication programs response risk prediction synergism therapeutic development therapy development therapy resistant trait tumor tumor DNA tumor growth tumor heterogeneity

项目摘要

High-grade, fast-growing breast cancers often display necrosis, usually within the tumor interior, where perfusion, nutrients, and oxygen are limited. Recent studies indicate that necrosis is not just an indicator of aggressive disease, but also a regulator of the aggressive phenotype, by impairing cancer drug delivery, promoting genomic evolution, and instigating metastasis to distant organs. However, we currently lack an understanding of the molecular mechanisms regulating necrosis development and consequently, there are no therapies to prevent the development of necrosis and its downstream effects on tumor aggression. For this application, we have developed animal models that enable the robust dissection of the tumor-host ecosystem in the necrotic interior. Our studies reveal that a secreted protein, angiopoietin-like 7 (Angptl7), is produced by tumor cells adjacent to the necrotic core and is a regulator of tumor core vasculature development. Importantly, when Angptl7 is suppressed genetically, tumor necrosis, tumor growth, and metastatic dissemination are each drastically reduced. Thus, necrosis development is not inevitable but rather is preventable by Angptl7 suppression. In the proposed work, we will combine studies using innovative animal models and breast cancer patient blood and tissue samples to test the hypothesis that the development of necrosis is a driving force for the evolution of highly metastatic and drug-resistant breast tumor cells. In Aim 1, we will use mouse models to test the hypothesis that Angptl7-induced necrosis limits delivery of chemotherapeutics to the tumor core, and that Angptl7 suppression synergizes with neoadjuvant chemotherapeutics to improve drug delivery and improve tumor killing. In Aim 2, we will use tissue from a large population-based cohort of early-stage breast cancer patients to determine how dilated blood vessels, an indicator of Angptl7-induced necrosis, influences risk of local and distant metastatic dissemination to predict benefit from adjuvant therapy. In Aim 3, we will apply genomic sequencing and circulating tumor DNA analysis in an innovative rat model for liquid biopsy studies to define the genomic signatures associated with Angptl7-induced necrosis. We will then determine the prognostic impact of a circulating tumor DNA signature of necrosis in human clinical samples. This work will define necrosis development as an engine for tumor diversification and aggression, and the clinical contexts both in early stage and metastatic settings where necrosis prevention could benetits patients with breast cancer and tumor types.

高级别、快速生长的乳腺癌通常表现为肿瘤内部坏死，